游离脂肪酸受体1
药理学
化学
低血糖
受体
胰岛素
医学
生物化学
内分泌学
兴奋剂
作者
Qiang Ren,Yiqing Fan,Lixin Yang,Mayu Shan,Wei Shi,Hai Qian
标识
DOI:10.1080/13543776.2023.2272649
摘要
Free fatty acid receptor 1 (FFAR1) is a potential therapeutic target for type 2 diabetes mellitus (T2DM) because it could clinically stimulate insulin release in a glucose-dependent manner without inducing hypoglycemia. In both the pharmaceutical industry and academic community, FFAR1 agonists have attracted considerable attention.The review presents a patent overview of FFAR1 modulators in 2020-2023, along with chemical structures, the biological activities and therapeutic applications of the representative compounds. Our patent survey used the major electronic databases, namely SciFinder, and Web of Science and Innojoy.Although FFAR1 agonists exhibit outstanding advantages, they are also associated with significant challenges. At present, reducing the molecular weight and overall lipophilicity and developing tissue-specific FFAR1 agonists may be the strategies for alleviating hepatotoxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI